Status:
COMPLETED
Weekly TP-HDFL in the Treatment of Advanced TCC
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Transitional Cell Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the efficacy of Weekly TP-HDFL in advanced transitional cell carcinoma in terms of response rate and overall survival.
Detailed Description
Transitional cell carcinoma(TCC)of urothelium,including bladder, ureter, and renal pelvis TCCs, was the most lethal urology malignancy in Taiwan. In 1995, approximately 1,300 new cases of TCC was diag...
Eligibility Criteria
Inclusion
- Pathology proven TCC Recurrent or metastatic TCC Muscle-invasive TCC
- Measurable disease
- Age\>18
- KPS\>60﹪
- Creatinine clearance\>35ml/min,
- AST/ALT \< or = 3.5times upper limits of normal reference values
- Bilirubin\< or = 2.0 mg/dl
- WBC \> or = 4,000/mm3, PLT \> or = 100,000/mm3
- Written informed consent
Exclusion
- Previous systemic chemo is not allowed
- TG \<70mg/dl
- CNS metastasis
- Life expectancy less than 3 months
Key Trial Info
Start Date :
October 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2004
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00154687
Start Date
October 1 2000
End Date
December 1 2004
Last Update
July 31 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Oncology, National Taiwan University Hospital
Taipei, Taiwan, 100